Last reviewed · How we verify
Ceftolozane-tazobactam
Ceftolozane-tazobactam is a Beta-lactam/beta-lactamase inhibitor combination Small molecule drug developed by National University of Singapore. It is currently FDA-approved for Complicated urinary tract infections (cUTI) including pyelonephritis, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), Complicated intra-abdominal infections (cIAI).
Ceftolozane-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting against enzymatic degradation.
Ceftolozane-tazobactam is a small molecule inhibitor of bacterial penicillin-binding protein. It is used to treat various conditions, including Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, and Cystic Fibrosis, among others.
At a glance
| Generic name | Ceftolozane-tazobactam |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination |
| Target | Penicillin-binding proteins (PBPs); bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftolozane is a fifth-generation cephalosporin that penetrates gram-negative bacterial cell walls and inhibits penicillin-binding proteins, disrupting peptidoglycan cross-linking and causing cell lysis. Tazobactam is a beta-lactamase inhibitor that irreversibly binds and inactivates bacterial beta-lactamases, preventing enzymatic destruction of ceftolozane and restoring activity against resistant organisms. This combination is particularly effective against Pseudomonas aeruginosa and other multidrug-resistant gram-negative pathogens.
Approved indications
- Complicated urinary tract infections (cUTI) including pyelonephritis
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Complicated intra-abdominal infections (cIAI)
Common side effects
- Diarrhea
- Nausea
- Headache
- Vomiting
- Hypersensitivity reactions
- Clostridioides difficile infection
Key clinical trials
- Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation (PHASE4)
- Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036) (PHASE1)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens (PHASE4)
- Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia (PHASE3)
- Nosocomial Infections in ECMO Patients
- Use of New Antibiotics in Sweden
- Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftolozane-tazobactam CI brief — competitive landscape report
- Ceftolozane-tazobactam updates RSS · CI watch RSS
- National University of Singapore portfolio CI
Frequently asked questions about Ceftolozane-tazobactam
What is Ceftolozane-tazobactam?
How does Ceftolozane-tazobactam work?
What is Ceftolozane-tazobactam used for?
Who makes Ceftolozane-tazobactam?
What drug class is Ceftolozane-tazobactam in?
What development phase is Ceftolozane-tazobactam in?
What are the side effects of Ceftolozane-tazobactam?
What does Ceftolozane-tazobactam target?
Related
- Drug class: All Beta-lactam/beta-lactamase inhibitor combination drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs); bacterial beta-lactamases
- Manufacturer: National University of Singapore — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Complicated urinary tract infections (cUTI) including pyelonephritis
- Indication: Drugs for Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Indication: Drugs for Complicated intra-abdominal infections (cIAI)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing